

Urukthapelstatin A, a Novel Cytotoxic Substance from Marine-derived *Mechercharimyces asporophorigenens* YM11-542

II. Physico-chemical Properties and Structural Elucidation

Yoshihide Matsuo, Kaneo Kanoh, Hiroshi Imagawa, Kyoko Adachi, Mugio Nishizawa, Yoshikazu Shizuri

Received: December 22, 2006 / Accepted: March 13, 2007

© Japan Antibiotics Research Association

Abstract The new cyclic peptide antibiotic, urukthapelstatin A, has been isolated from a culture of *Thermoactinomycetaceae* bacterium *Mechercharimyces asporophorigenens* YM11-542. The structure of urukthapelstatin A was elucidated by NMR, MS, Marfey analysis, chiral HPLC and X-ray crystal analyses.

Keywords urukthapelstatin A, cyclic peptide, cytotoxic, *Thermoactinomycetes*

Introduction

Urukthapelstatin A (**1**) is a thiopeptide antibiotic which contains three oxazoles and two thiazoles in its cyclic structure and is structurally related to mechercharstatin (former name, mechercharmycin) [1, 2] and YM-216391 [3, 4]. The fermentation, isolation and biological properties of **1** (Fig. 1) have been reported in the preceding paper [5]. This report describes the physico-chemical properties and structural determination of **1**, which was produced by *Mechercharimyces asporophorigenens* YM11-542.




Fig. 1 Structure of urukthapelstatin A (**1**).

Results

Physico-chemical Properties

The physico-chemical properties of **1** are summarized in Table 1. **1** was isolated as a white solid. It was soluble in DMSO, DMF, CHCl_3 and CH_2Cl_2 , poorly soluble in MeOH and MeCN, and insoluble in water. An analysis of low-resolution FAB-MS data in the positive and negative modes revealed its molecular mass to be 710. The molecular formula of **1** was established as $\text{C}_{34}\text{H}_{30}\text{N}_8\text{O}_6\text{S}_2$ by high-resolution FAB-MS data ($[\text{M}+\text{Na}]^+$: found, m/z 733.1616; calcd. for $\text{C}_{34}\text{H}_{30}\text{N}_8\text{O}_6\text{S}_2\text{Na}$, m/z 733.1627).

Structural Elucidation

In the $^1\text{H-NMR}$ spectrum, three methyl signals (δ_{H} 0.85, 0.86 and 1.50) and one vinyl methyl (δ_{H} 1.82) were observed. Five aromatic protons (δ_{H} 7.51, 2×7.55 and 2×8.34), four downfield singlets (δ_{H} 8.59, 8.69, 8.88 and 9.07), one olefinic proton (δ_{H} 6.62), and three exchangeable downfield proton signals (δ_{H} 8.75, 9.00 and 9.49) were also observed. The $^{13}\text{C-NMR}$ spectrum revealed 32 distinguishable carbon signals, of which there were 16 quaternary, 13 methine, 1 methylene and 4 methyl resonances. All of these 16 quaternary resonances were in

Y. Matsuo (Corresponding author), K. Kanoh, K. Adachi, Y. Shizuri: Marine Biotechnology Institute Co. Ltd., 3-75-1 Heita, Kamaishi, Iwate 026-0001, Japan,
E-mail: yoshihide.matsuo@mbio.jp

H. Imagawa, M. Nishizawa: Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan

Table 1 Physico-chemical properties of **1**

Appearance	White powder
MP (from CH ₂ Cl ₂ /MeOH)	311°C (decomp.)
Molecular formula	C ₃₄ H ₃₀ N ₈ O ₆ S ₂
FAB-MS (<i>m/z</i>)	
Positive	711 [M+H] ⁺ , 733 [M+Na] ⁺
Negative	709 [M-H] ⁻
HR-FAB-MS (<i>m/z</i>)	
Found	733.1616 [M+Na] ⁺
Calcd	733.1627
UV λ _{max} ^{MeCN} nm (log ε)	267 (4.35), 291 (4.52)
IR (KBr) cm ⁻¹	3393, 2921, 2851, 1654, 1507, 1459
[α] _D ²²	+38° (c 0.5, CHCl ₃)

the δ_C 123~170 range, again suggesting a peptide with a highly aromatic character. Collectively, the molecular formula, and the UV, IR and NMR signals revealed the compound to be similar to mechercharstatin [1, 2] and YM-216391 [4] which contain oxazoles and a thiazole in their structures. In particular, there was significant overlap between the NMR data for the compound and the published data for mechercharstatin and YM-216391 [1, 2, 4].

The ¹H- and ¹³C-NMR chemical shift assignments for **1** were based on 2D NMR analyses (COSY, TOCSY, HSQC, HMBC and ROESY) shown in Table 2. A detailed analysis of the ¹H-¹H COSY and TOCSY experiments revealed the partial structures of CH₃-CH=, CH₃-CHX-NH- and CH₃-CH₂-CH(-CH₃)-CHX-NH-, and a mono-substituted benzene moiety. The presence of oxazole and thiazole units was deduced by comparing the corresponding ¹H and ¹³C chemical shifts with those of mechercharstatin and YM-216391. ¹H and ¹³C chemical shifts and HMBC signals of **1** from aromatic protons to carbons; δ_H 9.07 to δ_C 135.50 and 155.11, δ_H 8.88 to δ_C 129.56 and 159.65, δ_H 8.69 to δ_C 141.93 and 161.08, and δ_H 8.59 to δ_C 147.79 and 157.26, suggest the existence of two oxazols and two thiazols in the structure.

The relationship of the spin networks was established from ¹H-¹³C long-range correlations in the HMBC spectrum and yielded three partial structures, which were assigned to a bithiazole-benzyloxazole moiety (C₁₅H₇N₃OS₂, partial structure **A**), one oxazole (C₃HNO, partial structure **B**), and an alanine and isoleucine-containing part (C₁₆H₂₂N₄O₄, partial structure **C**, Fig. 2). The HMBC correlations when ⁿJ_{CH} was set to 2 Hz, were observed from H-34 (δ_H 8.59) to C-2 (δ_C 135.50), and from H-6 (δ_H 8.88) to C-4 (δ_C 155.11). Consequently, C-1 of partial structure **A** was connected to C-2 of partial structure **B**, and C-4 of partial structure **B** was connected to C-6 of

partial structure **C**. In addition, the ROESY correlation of H-10 (δ_H 1.82) and N4-H (δ_H 9.49) revealed that a vinylmethyl part in partial structure **C** had a *Z* configuration (Fig. 2).

Although there is no signal between partial structure **A** and **C** in HMBC spectrum, the C-20/C-21 connection can be brought about by the comparison of the molecular formula C₃₄H₃₀N₈O₆S₂ with a total of each partial structures (**A**; C₁₅H₇N₃OS₂, **B**; C₃HNO, **C**; C₁₆H₂₂N₄O₄), enabling the planer structure of **1** to be obtained.

The absolute configuration of the alanine and isoleucine residues was determined by a Marfey analysis [6] and chiral HPLC analysis of the acid hydrolysate of **1**. The Marfey analysis clarified the existence of L-Ala in the acid hydrolysate of **1**, but D-Ile and D-*allo*-Ile were indistinguishable from the reversed-phase HPLC analysis of their FDAA derivatives. The chiral HPLC analysis successfully defined the absolute configuration of isoleucine as D-*allo*-Ile. Finally, the absolute stereochemistry of **1** was determined as shown in Fig. 1.

An X-ray crystallographic analysis was also performed to confirm the full structure of **1**. An adequate crystal was obtained by crystallization from CH₂Cl₂/MeOH (1 : 1). The crystal data and measurement conditions are summarized in the experimental section, and the ORTEP drawing shown in Fig. 3. The absolute configuration of **1** was ascertained from an X-ray anomalous dispersion of the S atom as shown in Fig. 1.

Discussion

The structure of **1** was determined by spectroscopic methods, chemical degradation, and by an X-ray crystallographic analysis. The structure of **1** was

Table 2 ^1H - and ^{13}C -NMR data for **1**

Position	^{13}C δ , mult.	^1H δ , mult., J (Hz)	HMBC
1	157.26, s		
2	135.50, s		
3	139.43, d	9.07, s	C-2, C-4
4	155.11, s		
5	129.56, s		
6	140.12, d	8.88, s	C-4*, C-5, C-7
7	159.65, s		
8	123.70, s		
9	128.78, d	6.62, q, 7.5	C-7, C-8, C-10
10	13.38, q	1.82, d, 7.5	C-7, C-8, C-9
11	170.30, s		
12	48.13, d	4.75, dq, 6.8, 7.5	C-11, C-13
13	19.80, q	1.50, d, 6.8	C-11, C-12
14	169.45, s		
15	58.45, d	4.52, dd, 8.3, 9.0	C-16, C-17, C-18, C-20
16	36.92, d	2.06, m	C-14, C-15, C-17, C-18, C-19
17	15.09, q	0.85, d, 6.8	C-15, C-16, C-18
18	25.24, t	1.09, m and 1.46, m	C-15, C-17, C-19
19	11.09, q	0.86, t, 7.5	C-16, C-18
20	159.95, s		
21	130.52, s		
22	151.00, s		
23	126.64, s		
24	127.78, d	8.34, d, 7.5	C-21*, C-22, C-26, C-28
25	128.30, d	7.55, dd, 6.8, 7.5	C-23, C-27
26	129.84, d	7.51, dd, 6.8, 6.8	C-24, C-28
27	128.30, d	7.55, dd, 6.8, 7.5	C-23, C-25
28	127.78, d	8.34, d, 7.5	C-21*, C-22, C-24, C-26
29	154.02, s		
30	141.93, s		
31	123.05, d	8.69, s	C-29, C-30, C-32
32	161.08, s		
33	147.79, s		
34	121.06, d	8.59, s	C-1, C-2*, C-32, C-33
N4-H	—	9.49, brs	C-7, C-8, C-9, C-11
N5-H	—	8.75, brd, 7.5	C-12, C-13, C-14
N6-H	—	9.00, br	

* HMBC correlations observed only when $^nJ_{\text{CH}}$ was set to 2 Hz.

characterized as a cyclic peptide containing L-Ala, D-allo-Ile and a unique bioxazole-bithiazole-phenyloxazole moiety. Compound **1** is structurally related to the 24-membered cyclic compound, including mechercharstatin isolated from another *Thermoactinomycetaceae* bacterium [1, 2], YM-216391 from *Streptomyces nobilis* [3, 4] and telomestatin that has been isolated from *Streptomyces anulatus* [7]. This class of cyclic peptides containing a sequential oxazole-thiazole moiety represents a new group

of antibiotics with highly potent activities. Further studies describing methods to improve the pharmaceutical properties of **1** will be reported elsewhere.

Experimental

General Procedures

Melting point (mp) values were determined with micro-




Fig. 2 2D NMR spectral data and partial structures of **1**.

—, COSY and TOCSY; —, HMBC; —, HMBC ($^nJ_{\text{CH}}=2\text{ Hz}$); —, ROESY.

melting point apparatus (Yanaco). Optical rotation values were measured with a SEPA-300 digital polarimeter (Horiba), and IR spectra were obtained with an FT/IR-430 infrared spectrometer (Jasco). NMR (500 and 750 MHz for ^1H) spectra were obtained with a Unity INOVA NMR spectrometer (Varian), and low- and high-resolution mass spectra were measured with a JMS-SX102A instrument (Jeol). The X-ray diffraction analysis was carried out on a Mac Science (Bruker Nonius) dip image plate diffractometer, using graphite-monochromated $\text{Mo } K\alpha$ radiation ($\lambda=0.71073\text{ \AA}$).

Marfey Analysis

Approximately $200\text{ }\mu\text{g}$ of **1** was hydrolyzed with $500\text{ }\mu\text{l}$ of 6 N HCl at 120°C for 16 hours. The solution was freeze-dried and partitioned between CHCl_3 and water. The aqueous layer was then freeze-dried and used for the Marfey analysis [6]. A sample and standard amino acids (L-Ala, DL-Ala, L-Ile and DL-Ile, 2 nmol each) were dissolved in $100\text{ }\mu\text{l}$ of 0.1 N NaHCO_3 , and $50\text{ }\mu\text{l}$ of a 0.5% FDAA-acetone solution (1-fluoro-2,4-dinitrophenyl-5-L-alanineamide, Marfey's reagent, Pierce) was added. The mixture was heated at 65°C for 10 minutes, cooled to room temperature, and $50\text{ }\mu\text{l}$ of 0.2 N HCl was added. Each $100\text{ }\mu\text{l}$ of the FDAA-derived mixture was directly analyzed by HPLC. The analysis of the FDAA derivatives was performed in a TSKgel ODS-80Ts column ($150\times 4.6\text{ mm}$, Tosoh Co.) maintained at 30°C with UV detection at 340 nm . MeOH, 0.1% TFA containing MeCN and 0.1% TFA containing water were used as the mobile phase in the linear-gradient elution mode (constant 25% MeOH, 0.1% TFA containing 10~50% MeCN for 22 minutes) at a flow rate of 1.0 ml/minute . The retention times of the FDAA derivatives of the amino acid hydrolysate were 11.55




Fig. 3 ORTEP drawing for **1**.

One of two molecules of urukthapelstatin A in a unit cell and co-crystallized solvent molecules are omitted for clarity.

minutes (L-Ala; D-Ala= 14.61 minutes) and 20.91 minutes (D-Ile and D-allo-Ile; L-Ile and L-allo-Ile= 17.79 minutes).

Chiral HPLC Analysis

To determine the absolute configuration of Ile, another hydrolysate of **1** was prepared. Approximately $500\text{ }\mu\text{g}$ of **1** was hydrolyzed with 1.0 ml of 6 N HCl at 117°C for 15 hours. The solution was partitioned three times between ethyl acetate and water. The aqueous layer was freeze-dried and dissolved in $200\text{ }\mu\text{l}$ of water, and $50\text{ }\mu\text{l}$ of the hydrolysate was analyzed by chiral HPLC in a Sumichiral OA-5000 column ($150\times 4.6\text{ mm}$, Sumika Chemical Analysis Service) maintained at 30°C with UV monitoring at 254 nm , using 5% i-propanol containing 2 mM CuSO_4 as the mobile phase at a flow rate of 1.0 ml/minute . The retention time of the acid hydrolysate of **1** was 12.32 minutes (D-allo-Ile; D-Ile= 15.83 minutes).

X-Ray Crystal Analysis

A suitable crystal was obtained by crystallization from $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (1 : 1). The ORTEP drawing is shown in Fig. 3. The absolute configuration of **1** was determined from an X-ray anomalous dispersion of the S atom as shown in Fig. 3.

The crystal used for the X-ray crystallographic analysis contained 3 molecules of CH_2Cl_2 , 2 molecules of H_2O and 2 molecules of **1** in a unit cell. Crystal data for **1**: $2(\text{C}_{34}\text{H}_{30}\text{N}_8\text{O}_6\text{S}_2)\cdot 2(\text{H}_2\text{O})\cdot 3(\text{CH}_2\text{Cl}_2)=\text{C}_{71}\text{H}_{70}\text{Cl}_6\text{N}_{16}\text{O}_{14}\text{S}_4$, colorless cube, $M_r=1712.413$, monoclinic $P2_1$, $a=10.5360(4)\text{ \AA}$, $b=24.3470(8)\text{ \AA}$, $c=15.9700(8)\text{ \AA}$, $\alpha=90.00^\circ$, $\beta=95.1770(10)^\circ$, $\gamma=90.00^\circ$, $V=4079.9(3)\text{ \AA}^3$, $Z=2$, $\rho_{\text{calcd}}=1.394\text{ mg/m}^3$, $\mu=0.384/\text{mm}$, $T=298\text{ K}$, 14144 measured reflections, 14122 independent reflections, 1000

parameters, GOF=1.062, and $R1$ ($wR2$)=0.0639 (0.1764). The measurements were carried out by a Mac Science (Bruker Nonius) dip image plate diffractometer, using graphite-monochromated $\text{Mo } K_{\alpha}$ radiation ($\lambda=0.71073 \text{ \AA}$). The crystal structure was solved by the direct method with SIR-97. Refinement was performed by full-matrix least-squares refinement on F^2 with SHELXL-97. CCDC 627198 contains supplementary crystallographic data to that presented in this paper. These data can be obtained free of charge from Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Acknowledgments We thank Dr. Ryuichi Sakai (Department of Marine Biosciences, School of Fisheries Sciences, Kitasato University) for measuring the high- and low-resolution FAB-MS data. We are also grateful for the technical assistance of Ms. Kumiko Kawahata and Ms. Tomoe Sasaki. This work was performed as part of the project entitled “Constructing the Genetic Resource Library of Unidentified Microbes Based on Genome Information” supported by New Energy and Industrial Technology Development Organization (NEDO).

References

1. Kanoh K, Matsuo Y, Adachi K, Imagawa H, Nishizawa M, Shizuri Y. Mechercharmycins A and B, cytotoxic substances from marine-derived *Thermoactinomyces* sp. YM3-251. *J Antibiot* 58: 289–292 (2005)
2. Kanoh K, Matsuo Y, Adachi K, Kasai H, Katsuta A, Shizuri Y, Imagawa H, Nishizawa M. Cytotoxic cyclic peptides from marine-derived Firmicutes. 47th Symp Chem Nat Prod: 211–216 (2005)
3. Sohda K, Nagai K, Yamori T, Suzuki K, Tanaka A. YM-216391, a novel cytotoxic cyclic peptide from *Streptomyces nobilis*. I. Fermentation, isolation and biological activities. *J Antibiot* 58: 27–31 (2005)
4. Sohda K, Hiramoto M, Suzumura K, Takebayashi Y, Suzuki K, Tanaka A. YM-216391, a novel cytotoxic cyclic peptide from *Streptomyces nobilis*. II. Physico-chemical properties and structure elucidation. *J Antibiot* 58: 32–36 (2005)
5. Matsuo Y, Kanoh K, Yamori T, Kasai H, Katsuta A, Adachi K, Shizuri Y. Urukthapelstatin A, a novel cytotoxic substance from marine-derived *Mechercharimyces asporophorigenens* YM11-542. I. Fermentation, isolation and biological activities. *J Antibiot* 60: 251–255 (2007)
6. Marfey P. Determination of D-amino acids. II. Use of a bifunctional reagent, 1,5-difluoro-2,4-dinitrobenzene. *Carlsberg Res Commun* 49: 591–596 (1984)
7. Shin-ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K, Hayakawa Y, Seto H. Telomestatin, a novel telomerase inhibitor from *Streptomyces anulatus*. *J Am Chem Soc* 123: 1262–1263 (2001)